The CPV offers a translational viral vector development service from the proof of concept to pre-clinical vector production intended to use for toxicology studies. Since 1996, the vector core has developed processes for production and characterization of viral vectors derived from adeno-associated virus (AAV) serotypes-1 to rh10 and Adenovirus at research grade. The R&D group is focusing on the development of new production tools, production and purification processes for clinical grade viral vectors, as well as Quality Controls for clinical applications. These developments are intended to be transferred to pharmaceutical platform for production and characterization of clinical lots.
- 14 microbiological security stations II
- 21 CO2 incubators
- Nano Icellis bioreactors
- Suspension cell culture in bioreactors
- P3 and double door autoclave
- Liquid chromatograph chains
The platform is accessible to academic research units and companies.